Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MMMW Mass Megawatts Makes Progress Toward Several Solar Project Sales in Central Massachusetts
https://www.globenewswire.com/news-release/2022/12/28/2580146/0/en/Mass-Megawatts-Makes-Progress-Toward-Several-Solar-Project-Sales-in-Central-Massachusetts.html
$XALL 0024 +20% green heading into power hour!
*** $NAK Copper Mining ****
$SANP the next runner, nice lotto here!
$APSI .75 hod hitting! On watch for Super 8k expected to hit at any time. Tradition Transport 100M+ merger under 10M mkt cap.
Docs for acquisition are in legal review. All parties are working diligently to close transaction in a timely fashion. Super 8-K is being drafted for filing with SEC upon signing of definitive agreements. $APSI will pursue up listing subsequent to acquisition completion.
— APSI - Aqua Power Systems Inc (@inc_apsi) November 17, 2022
$GMPR Gourmet Provisions International Corp. (GMPR) Now Selling Gluten-Free Pizzas in Buehler's Fresh Foods Grocery Stores https://finance.yahoo.com/news/gourmet-provisions-international-corp-gmpr-130000912.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$CURR News: CURE Pharmaceutical Letter to Shareholders
Investment in New Marketing Strategies Showing Encouraging Early Results
Enhanced Instagram & Media campaigns featuring Nicole Kidman highlighting Seratopical Revolution
Incubator Strategy Initiated with New Market Disruptor Products arriving 1H2023
SHERMAN OAKS, CA / ACCESSWIRE / December 15, 2022 / CURE Pharmaceutical Holding Corp. (OTCQB:CURR) CEO Nancy Duitch is providing an update to its shareholders on positive recent developments in the evolution and progress of the Company.
Dear Shareholders:
We would like to thank all of you for your continued support during this exciting time in our company's history. We also want to share some of the progress we have made in the short period of time since the asset sale at the end of July 2022 which allowed us to invest in the Company's transformational products and innovative marketing campaigns. We have been very busy executing on our strategy which we believe will increase shareholder value.
CURE's new business model is now focused on ‘The Future of Innovative Wellness' utilizing our broad platform technologies. The new and exciting delivery system technologies we are creating in the surging wellness and beauty markets position us well for accelerating sales of our very high margin innovative products. Technology and innovation along with our team's execution will help to distinguish Cure in the marketplace.
The Company's short and long-term growth strategy is to increase revenue with high margin products. We will do this by using our incubator strategy to grow the patent and product portfolios. Additionally, we will monetize the patented technology through multiple revenue streams including strategic partnerships and transactions. These initiatives, along with the Company's relationships with Nicole Kidman and other major social media influencers, will also help propel its wellness and beauty brands to become household names and to become a house of respected and recognizable quality brands.
The Value Proposition of the Company is supported by these pillars:
Technology - Providing innovative wellness solutions to fill current market gaps by ordinary supplement delivery systems.
Strong Patent Portfolio - Portfolio of over 15 critical patents, issued and pending. Monetize owned IP through licensing/asset sale of the technology while developing new proprietary patents.
Established Network - A trusted and reliable brand that is recognized for quality and commitment to its customers.
Growth Plans - Multiple strategies that will be used to expand patents and product offerings, improve cash flow and ensure profitability to include, strategic non-dilutive transactions, geographic licensing, mergers or acquisitions and joint venture partnerships.
Management Expertise - The team has several decades of experience in the wellness and beauty sectors utilizing innovative products with cutting-edge intellectual property.
Supporting the strategic direction of the Company, the research firm of McKinsey & Company has estimated consumer spending on wellness products and services to be more than $450 billion in the United States, and growing at more than 5 percent annually, with global sales topping $1.5 trillion.They stated: "Consumers are eager to find solutions that work. The companies that thrive will be those that can identify and target unmet needs through offerings that are thoughtful, differentiated, tailored, and - increasingly - that target multiple dimensions of wellness."
Along with the wellness market place the Company is also heavily involved in the beauty industry which exceeds $530 billion in the U.S. alone. This is an arena in which the Company has excelled in the past and will continue to grow due to our branding and marketing expertise with a multi-channel Return on Investment advertising strategy. We are very proud of the unique and cutting-edge delivery system technologies which differentiate our products from those of other companies, and that is allowing us to grow with a limited amount of competition. We recently completed our new Seralabshealth.com website which is very user friendly and is showing huge improvement in conversions which leads to increased sales.
We also recently hired Rick Petry who is one of the most renowned writers and direct marketers. In addition, we brought in Tracy Jankowski as our Vice President of Digital Marketing who is an expert in women's products and who has turned around our digital marketing and branding strategies in just seven short weeks upgrading our internal team without adding additional G&A expense.
We have worked at warp speed on building out our technology and product development as well as our A-plus team the past four months. Thus, giving us a jump start for Q1 2023. Most importantly, our high gross margin products are priced so they are affordable for everyone in these tough economic times. There is an interesting WSJ article called the "Lipstick Index" which outlines what consumers look for during these times: affordable products that make consumers feel better about themselves which falls into our categories and price points.
Link to WSJ article: https://www.wsj.com/articles/the-lipstick-index-is-back-11669256641?st=phgh12u9x1q58wg&reflink=desktopwebshare_permalink
As we have previously reported, other important company developments already include strong sales results and revenue growth. Plus, we completed sale of a portion of our platform technology intellectual property portfolio and related assets in July 2022 for $20 million of non-dilutive capital in total consideration. A portion of the cash proceeds was used to pay down certain debt obligations and the balance is being used for working capital and to grow the Company's intellectual property portfolio and its wellness and beauty brands. The Company retained 15 of its patents and will continue to be an incubator for future technologies and patents, which it intends to monetize through the commercialization of the technologies through product development or through the licensing/sale of the technologies.
CURE'S wholly owned subsidiary, The Sera Labs, also announced that six SKUs of its Seratopical Revolution skincare line with P3P, our proprietary delivery system, are now being sold at over 1,372 Walmart Stores as well as on Amazon.com.
Sera Labs also has garnered placement for its revolutionary oral thin film strip, Nutri-Strips™ on shelves at CVS, Amazon.com and Target.com. Nutri-Strips are proprietary to Sera Labs and are the result of years of research.
We are also fortunate to have enhanced engagement of our Brand Ambassador, award winning actress Nicole Kidman who has steadfastly been so supportive in product development and continues to help us with posting, videos, and PR (including her current series of Instagram posts for the holidays highlighted in Daily Mail Article linked below) which together with our quality products builds consumer awareness and trust. We have recently enhanced the reach and visibility of Nicole as part of the launch of our new transformational Seratopical Revolution campaign and the unveiling of our cutting-edge new delivery system for our plant-based skincare line. Nicole Kidman and I will have more prominence in these multi-faceted marketing programs including recent articles like the ones Daily Mail, Forbes and Impact Wealth. To view the articles, click on the following links:
Daily Mail Dec 12, 2022, Nicole Kidman reveals the secret to her age-defying skin
Forbes Oct 31, 2022 - Nicole Kidman Talks Skincare-And The Beauty Essentials She Always Has In Her Bag
Impact Wealth Oct 31, 2022 - The Powerful Impact of Beauty Market Revealed by CEO Nancy Duitch
Recent key operational highlights included the following:
Revenue in the third quarter surged 32.1% year-over-year and 58.9% sequentially from Q2 2022 to $1.8 million with further increases expected in Q4.
Gross margins for the third quarter improved by 123 basis points to 80.0% in 2022 compared to the same period in 2021 with expectations of continuing high margin sales with our new marketing initiatives.
SG&A expenses (excluding non-cash charges) for the third quarter decreased by $0.1 million in 2022 compared to 2021.
Cost reductions and operating leverage helped narrow operating loss (excluding non-cash charges) by $0.6 million in 2022 versus 2021 despite enhanced marketing investment.
We are very pleased with the direction of our operating results and accelerating sales in the third quarter which reflect the improving trajectory of the business. The proceeds from the recent asset sale will enable us to invest in the future of the Company. Our margin expansion initiatives continue to deliver results, and we are continuing our efforts to reduce SG&A expenses. We are also very excited about the launches of the advertising and marketing campaigns for our Nutri-Strips and Seratopical Revolution lines. And get ready for the launch of our exciting market disruptors developed by our team of formulators led by Rob Davidson, our Chairman and Chief Technical Officer, in the first half of 2023 which look very promising for the Company.
Sincerely,
Nancy Duitch, CEO
CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical is a broad platform technology company that develops proprietary nutraceutical and topical delivery systems and currently holds fifteen patents. The technology offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new innovative technology that is part of its incubator strategy.
About The Sera Labs, Inc.
The Sera Labs, Inc. ("Sera Labs"), a wholly-owned subsidiary of CURE, is a trusted leader in the wellness and beauty sectors utilizing cutting edge technology and high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale and is strategically positioned to grow its beauty and wellness products into household brands. Sera Labs products are sold Direct to Consumer with a subscribe and save option, as well as in major national drug, grocery and mass retailers. For more information visit: Seratopicalrevolution.com, Seratopical.com, Seralabshealth.com and follow Sera Labs on Instagram at @seratopical, as well as on Twitter and Facebook.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
Contacts:
Investor Relations
Hanover International Inc.
(760) 564-7400
investor@curepharma.com
SOURCE: CURE Pharmaceutical Holding Corp.
View source version on accesswire.com:
https://www.accesswire.com/731950/CURE-Pharmaceutical-Letter-to-Shareholders
$BLEG & $SMPP Sells Magic 1 Promotions, LLC For $1 Million
https://tinyurl.com/5daz85a5
$ZRFY Zerify Named Leader in Secure Video Conferencing Solutions by Aite-Novarica Group
Industry analyst group finds that as hybrid work is here to stay, organizations realize video conferencing carries the same security risk as other web applications
https://www.globenewswire.com/news-release/2022/12/15/2574486/0/en/Zerify-Named-Leader-in-Secure-Video-Conferencing-Solutions-by-Aite-Novarica-Group.html
$CLIS - ClickStream Corp. announces that its subsidiary Nifter™ is leveraging the expertise in estates and trusts by newly appointed CEO, Michael J. Smith to launch one of the NFTs market's first estate valuation and NFT programs for estates, athletes, and collectors. The estate & trusts program will fast-track Nifter™’s onboarding of valuable art and memorabilia to their "Value Based NFT" marketplace and develop best practices for the crypto industry’s shift to NFTs with utility and value.
https://www.businesswire.com/news/home/20221208005380/en/Following-Nifter%E2%84%A2%E2%80%99s-Launch-at-Art-Basel-with-over-5000-Event-Attendees-3-Million-Social-Views-Nifter-Announces-their-NFT-Trust-Estate-Program
$BOMO 0002's loading zone while you can
Agree, under .01 a steal!
$PSWW
$AITX Investor Open House and RAD Technology Reveal
$PSWW Monster run coming...
$LUDG - Ludwig Enterprises, Inc. has announced the acquisition of a nutraceutical formula from Xikoz, Inc. with a planned product release through MyRNA for Life, Inc. in Q1 of 2023. The has acquired an in-perpetuity license from Xikoz, Inc, of Sheridan, WY, for a dietary supplement formula. MyRNA will develop and market this nutraceutical formula, MyRNA for Life™. The compounds within this formula have the potential to modulate inflammatory conditions that are the root causes of many chronic diseases, including but not limited to cancer, heart disease, and diabetes.
https://finance.yahoo.com/news/ludwig-enterprises-acquires-cutting-edge-120000551.html
$PVSP News and Headlines https://www.barchart.com/stocks/quotes/PVSP/news
$MASN on alert, big increase in revenues for the company: Maison Luxe ($MASN) revenues grew 35% compared to the quarter ended September 30, 2021 $AVXL $COSM $MASN https://www.benzinga.com/pressreleases/22/12/ab29954104/maison-luxe-masn-revenues-grew-35-compared-to-the-quarter-ended-september-30-2021 via @Benzinga
$PVSP the LOI, Zen will acquire the assets of BCCTG for cash, paid from contributed revenues with a monthly upper limit and cash neutral on current pre-transaction financials. In addition, Pervasip will provide a group of BCCTG owners, investors and employees 10.2% of Pervasip’s fully diluted equity in the form of restricted preferred stock.
“As outlined in our 24-months roadmap, which we published on September 6, 2022, this acquisition checks 2 of our boxes on the list of strategic objectives to be accomplished by year’s end 2022,” said German Burtscher, Pervasip’s CEO. “Not only will it immediately add revenue upon final closing of the deal, but it will also add infrastructure, expertise and a handful of well-regarded brands to our brand lineup. Brian Martin and his team at Emerald City Cultivation and Dabco have done incredible work and built a strong and highly respected company. We are excited to add the BCCTG team to our Washington operation and fill critical open positions with market leading expertise. Final terms will be released upon closing, projected for the end of November 2022.”
Emerald City Cultivation and Dabco are brands known for high quality concentrates product (dab and vape) and with over 40,000 followers have established a well-deserved fanbase.
“Combining forces with Artizen and offering a complete and potent product lineup to Washington retailers has been a vision of mine for some time now,” said Brian Martin, Founder and President of BCCTG and Emerald City Cultivation. “Being able to do this, take care of our investors who have been with us from the beginning of this venture, and join the Artizen team is a wonderful opportunity. Artizen is one of the original Washington State cannabis brands and our combined lineup will allow retailers to offer a variety of products across multiple price points, all from a single trusted partner. Combining our assets and experience will also allow us to enter markets outside of Washington and take our vision and duplicate it in other markets. Look out for more announcements regarding new products over the next few weeks and months.”
$PVSP the execution of a letter of intent (“LOI”) to acquire substantially all of the assets of BCCTG LLC (“BCCTG”).
BCCTG, owner of various brands, including Emerald City Cultivation, Emerald City Cured, Dabco, Dabs4Less and Vapes4less has agreed to terms to be acquired by ZAM, combining its brands and concentrate offerings with ZAM’s Artizen brands to form a powerful portfolio of brands, covering flower, pre-roll, dabbable concentrates and vape products.
BCCTG’s brands, which generate $4 million in annualized revenues, manufactured in a state-of-the-art laboratory. The terms include acquisition of all BCCTG assets, including its brands, access to a Tier 2 producer/processor license and a turnkey laboratory which will be used to also manufacture new products under the Artizen brand.
According to the terms of the LOI, Zen will acquire the assets of BCCTG for cash, paid from contributed revenues with a monthly upper limit and cash neutral on current pre-transaction financials. In addition, Pervasip will provide a group of BCCTG owners, investors and employees 10.2% of Pervasip’s fully diluted equity in the form of restricted preferred stock.
“As outlined in our 24-months roadmap, which we published on September 6, 2022, this acquisition checks 2 of our boxes on the list of strategic objectives to be accomplished by year’s end 2022,” said German Burtscher, Pervasip’s CEO. “Not only will it immediately add revenue upon final closing of the deal, but it will also add infrastructure, expertise and a handful of well-regarded brands to our brand lineup. Brian Martin and his team at Emerald City Cultivation and Dabco have done incredible work and built a strong and highly respected company. We are excited to add the BCCTG team to our Washington operation and fill critical open positions with market leading expertise. Final terms will be released upon closing, projected for the end of November 2022.”
Emerald City Cultivation and Dabco are brands known for high quality concentrates product (dab and vape) and with over 40,000 followers have established a well-deserved fanbase.
“Combining forces with Artizen and offering a complete and potent product lineup to Washington retailers has been a vision of mine for some time now,” said Brian Martin, Founder and President of BCCTG and Emerald City Cultivation. “Being able to do this, take care of our investors who have been with us from the beginning of this venture, and join the Artizen team is a wonderful opportunity. Artizen is one of the original Washington State cannabis brands and our combined lineup will allow retailers to offer a variety of products across multiple price points, all from a single trusted partner. Combining our assets and experience will also allow us to enter markets outside of Washington and take our vision and duplicate it in other markets. Look out for more announcements regarding new products over the next few weeks and months.”
$PVSP Big News Alert: SEATTLE, WASHINGTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTC: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, together with Zen Asset Management LLC (“ZAM”) today announced the execution of a letter of intent (“LOI”) to acquire substantially all of the assets of BCCTG LLC (“BCCTG”).
BCCTG, owner of various brands, including Emerald City Cultivation, Emerald City Cured, Dabco, Dabs4Less and Vapes4less has agreed to terms to be acquired by ZAM, combining its brands and concentrate offerings with ZAM’s Artizen brands to form a powerful portfolio of brands, covering flower, pre-roll, dabbable concentrates and vape products.
BCCTG’s brands, which generate $4 million in annualized revenues, manufactured in a state-of-the-art laboratory. The terms include acquisition of all BCCTG assets, including its brands, access to a Tier 2 producer/processor license and a turnkey laboratory which will be used to also manufacture new products under the Artizen brand.
According to the terms of the LOI, Zen will acquire the assets of BCCTG for cash, paid from contributed revenues with a monthly upper limit and cash neutral on current pre-transaction financials. In addition, Pervasip will provide a group of BCCTG owners, investors and employees 10.2% of Pervasip’s fully diluted equity in the form of restricted preferred stock.
“As outlined in our 24-months roadmap, which we published on September 6, 2022, this acquisition checks 2 of our boxes on the list of strategic objectives to be accomplished by year’s end 2022,” said German Burtscher, Pervasip’s CEO. “Not only will it immediately add revenue upon final closing of the deal, but it will also add infrastructure, expertise and a handful of well-regarded brands to our brand lineup. Brian Martin and his team at Emerald City Cultivation and Dabco have done incredible work and built a strong and highly respected company. We are excited to add the BCCTG team to our Washington operation and fill critical open positions with market leading expertise. Final terms will be released upon closing, projected for the end of November 2022.”
Emerald City Cultivation and Dabco are brands known for high quality concentrates product (dab and vape) and with over 40,000 followers have established a well-deserved fanbase.
“Combining forces with Artizen and offering a complete and potent product lineup to Washington retailers has been a vision of mine for some time now,” said Brian Martin, Founder and President of BCCTG and Emerald City Cultivation. “Being able to do this, take care of our investors who have been with us from the beginning of this venture, and join the Artizen team is a wonderful opportunity. Artizen is one of the original Washington State cannabis brands and our combined lineup will allow retailers to offer a variety of products across multiple price points, all from a single trusted partner. Combining our assets and experience will also allow us to enter markets outside of Washington and take our vision and duplicate it in other markets. Look out for more announcements regarding new products over the next few weeks and months.”
$PVSP Pervasip Announces 3rd Quarter Financials https://finance.yahoo.com/news/pervasip-announces-3rd-quarter-financials-130000191.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$MASN huge news out!! https://finance.yahoo.com/news/maison-luxe-announces-additional-250-130000434.html
$ALST AllStar Health's (OTC:ALST) Provides Virtual Introduction to the "Sports Metaverse - MegaMall" Watch Now!
https://www.accesswire.com/730808/AllStar-Healths-OTCALST-Provides-Virtual-Introduction-to-the-Sports-Metaverse-MegaMall-Watch-Now
$PVSP (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, together with Zen Asset Management LLC (“ZAM”) today announced the execution of a letter of intent (“LOI”) to acquire substantially all of the assets of BCCTG LLC (“BCCTG”).
BCCTG, owner of various brands, including Emerald City Cultivation, Emerald City Cured, Dabco, Dabs4Less and Vapes4less has agreed to terms to be acquired by ZAM, combining its brands and concentrate offerings with ZAM’s Artizen brands to form a powerful portfolio of brands, covering flower, pre-roll, dabbable concentrates and vape products.
BCCTG’s brands, which generate $4 million in annualized revenues, manufactured in a state-of-the-art laboratory. The terms include acquisition of all BCCTG assets, including its brands, access to a Tier 2 producer/processor license and a turnkey laboratory which will be used to also manufacture new products under the Artizen brand.
According to the terms of the LOI, Zen will acquire the assets of BCCTG for cash, paid from contributed revenues with a monthly upper limit and cash neutral on current pre-transaction financials. In addition, Pervasip will provide a group of BCCTG owners, investors and employees 10.2% of Pervasip’s fully diluted equity in the form of restricted preferred stock.
“As outlined in our 24-months roadmap, which we published on September 6, 2022, this acquisition checks 2 of our boxes on the list of strategic objectives to be accomplished by year’s end 2022,” said German Burtscher, Pervasip’s CEO. “Not only will it immediately add revenue upon final closing of the deal, but it will also add infrastructure, expertise and a handful of well-regarded brands to our brand lineup. Brian Martin and his team at Emerald City Cultivation and Dabco have done incredible work and built a strong and highly respected company. We are excited to add the BCCTG team to our Washington operation and fill critical open positions with market leading expertise. Final terms will be released upon closing, projected for the end of November 2022.”
Emerald City Cultivation and Dabco are brands known for high quality concentrates product (dab and vape) and with over 40,000 followers have established a well-deserved fanbase.
“Combining forces with Artizen and offering a complete and potent product lineup to Washington retailers has been a vision of mine for some time now,” said Brian Martin, Founder and President of BCCTG and Emerald City Cultivation. “Being able to do this, take care of our investors who have been with us from the beginning of this venture, and join the Artizen team is a wonderful opportunity. Artizen is one of the original Washington State cannabis brands and our combined lineup will allow retailers to offer a variety of products across multiple price points, all from a single trusted partner. Combining our assets and experience will also allow us to enter markets outside of Washington and take our vision and duplicate it in other markets. Look out for more announcements regarding new products over the next few weeks and months.”
$PVSP (OTC: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, together with Zen Asset Management LLC (“ZAM”) today announced the execution of a letter of intent (“LOI”) to acquire substantially all of the assets of BCCTG LLC (“BCCTG”).
BCCTG, owner of various brands, including Emerald City Cultivation, Emerald City Cured, Dabco, Dabs4Less and Vapes4less has agreed to terms to be acquired by ZAM, combining its brands and concentrate offerings with ZAM’s Artizen brands to form a powerful portfolio of brands, covering flower, pre-roll, dabbable concentrates and vape products.
BCCTG’s brands, which generate $4 million in annualized revenues, manufactured in a state-of-the-art laboratory. The terms include acquisition of all BCCTG assets, including its brands, access to a Tier 2 producer/processor license and a turnkey laboratory which will be used to also manufacture new products under the Artizen brand.
According to the terms of the LOI, Zen will acquire the assets of BCCTG for cash, paid from contributed revenues with a monthly upper limit and cash neutral on current pre-transaction financials. In addition, Pervasip will provide a group of BCCTG owners, investors and employees 10.2% of Pervasip’s fully diluted equity in the form of restricted preferred stock.
“As outlined in our 24-months roadmap, which we published on September 6, 2022, this acquisition checks 2 of our boxes on the list of strategic objectives to be accomplished by year’s end 2022,” said German Burtscher, Pervasip’s CEO. “Not only will it immediately add revenue upon final closing of the deal, but it will also add infrastructure, expertise and a handful of well-regarded brands to our brand lineup. Brian Martin and his team at Emerald City Cultivation and Dabco have done incredible work and built a strong and highly respected company. We are excited to add the BCCTG team to our Washington operation and fill critical open positions with market leading expertise. Final terms will be released upon closing, projected for the end of November 2022.”
Emerald City Cultivation and Dabco are brands known for high quality concentrates product (dab and vape) and with over 40,000 followers have established a well-deserved fanbase.
“Combining forces with Artizen and offering a complete and potent product lineup to Washington retailers has been a vision of mine for some time now,” said Brian Martin, Founder and President of BCCTG and Emerald City Cultivation. “Being able to do this, take care of our investors who have been with us from the beginning of this venture, and join the Artizen team is a wonderful opportunity. Artizen is one of the original Washington State cannabis brands and our combined lineup will allow retailers to offer a variety of products across multiple price points, all from a single trusted partner. Combining our assets and experience will also allow us to enter markets outside of Washington and take our vision and duplicate it in other markets. Look out for more announcements regarding new products over the next few weeks and months.”
$PVSP $1.6 Million in August Revenues and 3rd Quarter Guidance https://finance.yahoo.com/news/pervasip-announces-1-6-million-131500755.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
iQSTEL, Inc. - IQST announced a 52% increase in revenue for the month of November reaching $10 million (based on preliminary accounting) compared to $6.6 million for the same period in 2021. The company’s revenue YTD through the end of November is $84.5 million.
https://finance.yahoo.com/news/iqst-iqstel-expects-meet-surpass-134600812.html
$HNRC Houston Natural Resources Corp Dividend Update
https://www.prnewswire.com/news-releases/hnrc-updates-shareholders-on-dividend-301696766.html
$AABB Report Estimates Over $800 Million Gold and Silver Value in Mexico https://finance.yahoo.com/news/asia-broadband-ore-stockpile-evaluation-130000857.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$PVSP Pervasip Corp. (OTC: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, together with Zen Asset Management LLC (“ZAM”) today announced the execution of a letter of intent (“LOI”) to acquire substantially all of the assets of BCCTG LLC (“BCCTG”).
BCCTG, owner of various brands, including Emerald City Cultivation, Emerald City Cured, Dabco, Dabs4Less and Vapes4less has agreed to terms to be acquired by ZAM, combining its brands and concentrate offerings with ZAM’s Artizen brands to form a powerful portfolio of brands, covering flower, pre-roll, dabbable concentrates and vape products.
BCCTG’s brands, which generate $4 million in annualized revenues, manufactured in a state-of-the-art laboratory. The terms include acquisition of all BCCTG assets, including its brands, access to a Tier 2 producer/processor license and a turnkey laboratory which will be used to also manufacture new products under the Artizen brand.
According to the terms of the LOI, Zen will acquire the assets of BCCTG for cash, paid from contributed revenues with a monthly upper limit and cash neutral on current pre-transaction financials. In addition, Pervasip will provide a group of BCCTG owners, investors and employees 10.2% of Pervasip’s fully diluted equity in the form of restricted preferred stock.
“As outlined in our 24-months roadmap, which we published on September 6, 2022, this acquisition checks 2 of our boxes on the list of strategic objectives to be accomplished by year’s end 2022,” said German Burtscher, Pervasip’s CEO. “Not only will it immediately add revenue upon final closing of the deal, but it will also add infrastructure, expertise and a handful of well-regarded brands to our brand lineup. Brian Martin and his team at Emerald City Cultivation and Dabco have done incredible work and built a strong and highly respected company. We are excited to add the BCCTG team to our Washington operation and fill critical open positions with market leading expertise. Final terms will be released upon closing, projected for the end of November 2022.”
Emerald City Cultivation and Dabco are brands known for high quality concentrates product (dab and vape) and with over 40,000 followers have established a well-deserved fanbase.
“Combining forces with Artizen and offering a complete and potent product lineup to Washington retailers has been a vision of mine for some time now,” said Brian Martin, Founder and President of BCCTG and Emerald City Cultivation. “Being able to do this, take care of our investors who have been with us from the beginning of this venture, and join the Artizen team is a wonderful opportunity. Artizen is one of the original Washington State cannabis brands and our combined lineup will allow retailers to offer a variety of products across multiple price points, all from a single trusted partner. Combining our assets and experience will also allow us to enter markets outside of Washington and take our vision and duplicate it in other markets. Look out for more announcements regarding new products over the next few weeks and months.”
$PVSP (GLOBE NEWSWIRE) -- Pervasip Corp. (OTC: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, together with Zen Asset Management LLC (“ZAM”) today announced the execution of a letter of intent (“LOI”) to acquire substantially all of the assets of BCCTG LLC (“BCCTG”).
BCCTG, owner of various brands, including Emerald City Cultivation, Emerald City Cured, Dabco, Dabs4Less and Vapes4less has agreed to terms to be acquired by ZAM, combining its brands and concentrate offerings with ZAM’s Artizen brands to form a powerful portfolio of brands, covering flower, pre-roll, dabbable concentrates and vape products.
BCCTG’s brands, which generate $4 million in annualized revenues, manufactured in a state-of-the-art laboratory. The terms include acquisition of all BCCTG assets, including its brands, access to a Tier 2 producer/processor license and a turnkey laboratory which will be used to also manufacture new products under the Artizen brand.
According to the terms of the LOI, Zen will acquire the assets of BCCTG for cash, paid from contributed revenues with a monthly upper limit and cash neutral on current pre-transaction financials. In addition, Pervasip will provide a group of BCCTG owners, investors and employees 10.2% of Pervasip’s fully diluted equity in the form of restricted preferred stock.
“As outlined in our 24-months roadmap, which we published on September 6, 2022, this acquisition checks 2 of our boxes on the list of strategic objectives to be accomplished by year’s end 2022,” said German Burtscher, Pervasip’s CEO. “Not only will it immediately add revenue upon final closing of the deal, but it will also add infrastructure, expertise and a handful of well-regarded brands to our brand lineup. Brian Martin and his team at Emerald City Cultivation and Dabco have done incredible work and built a strong and highly respected company. We are excited to add the BCCTG team to our Washington operation and fill critical open positions with market leading expertise. Final terms will be released upon closing, projected for the end of November 2022.”
Emerald City Cultivation and Dabco are brands known for high quality concentrates product (dab and vape) and with over 40,000 followers have established a well-deserved fanbase.
“Combining forces with Artizen and offering a complete and potent product lineup to Washington retailers has been a vision of mine for some time now,” said Brian Martin, Founder and President of BCCTG and Emerald City Cultivation. “Being able to do this, take care of our investors who have been with us from the beginning of this venture, and join the Artizen team is a wonderful opportunity. Artizen is one of the original Washington State cannabis brands and our combined lineup will allow retailers to offer a variety of products across multiple price points, all from a single trusted partner. Combining our assets and experience will also allow us to enter markets outside of Washington and take our vision and duplicate it in other markets. Look out for more announcements regarding new products over the next few weeks and months.”
$MASN website, learn more about it https://www.maisonluxeny.com/
$CURR is moving into a new business model focused on the company's very popular lines of wellness and anti-aging products. The latest financial results illustrate the company's growing success on this new path and with no dilution based financing.
CURE Pharmaceutical Reports Third Quarter 2022 Results With Strong Sequential and Year Over Year Revenue Increases and Continued High Margins
New Marketing Programs Showing Encouraging Early Results
SHERMAN OAKS, CA / ACCESSWIRE / November 22, 2022 / CURE Pharmaceutical Holding Corp. (OTCQB:CURR) ("CURE" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the quarter ended September 30, 2022.
Key operational highlights included the following:
Revenue in the third quarter surged 32.1% year-over-year and 58.9% sequentially from Q2 2022 to $1.8 million with further increases expected in Q4.
Gross margins for the third quarter improved by 123 basis points to 80.0% in 2022 compared to the same period in 2021 with expectations of continuing high margin sales with our new marketing initiatives.
SG&A expenses (excluding non-cash charges) for the third quarter decreased by $0.1 million in 2022 compared to 2021.
Cost reductions and operating leverage helped narrow operating loss (excluding non-cash charges) by $0.6 million in 2022 versus 2021 despite enhanced marketing investment.
"We are very pleased with our results and accelerating sales in the third quarter which reflect the improving trajectory of the business. The proceeds from the recent asset sale will enable us to invest in the future of the Company. Our margin expansion initiatives continue to deliver results, and we are continuing our efforts to reduce SG&A expenses to maximize operating leverage. We are also very excited about the launches of the advertising and marketing campaigns for our Nutri-Strips and Seratopical Revolution lines, both of which have proprietary delivery system technologies. Lastly, the new technologies that Rob Davidson and his team are developing for the Company look very promising," said Nancy Duitch, Cure Pharmaceutical CEO.
Operational Highlights
Other operational highlights during the third quarter of 2022 included:
CURE completed the sale of a portion of its platform technology intellectual property portfolio and related assets in July 2022 for $20 million of non-dilutive capital in total consideration. A portion of the cash proceeds was used to pay down certain debt obligations and the balance will be used for working capital and to grow the Company's intellectual property portfolio and its wellness and beauty brands. The Company retained 15 of its patents and will continue to be an incubator for future technologies and patents, which it intends to monetize through the commercialization of the technologies through product development or through the licensing or sale of the technologies.
The Company is focused on becoming the future of wellness with its long-term growth strategy to increase revenue with high margins by using its incubator strategy, product development and marketing and through strategic partnerships and geographic licensing deals. These initiatives, along with the Company's relationships with Nicole Kidman and other major social media influencers, will also help propel its health and beauty brands to become household names and the Company to become a genuine house of recognizable and respected quality brands.
CURE's wholly owned subsidiary, The Sera Labs, also announced that six SKUs of its Seratopical Revolution skincare line with P3P, the proprietary delivery system, are now being sold at 1,372 Walmart Stores as well as on Amazon.com.
Sera Labs also has garnered placement for its revolutionary oral thin film strip, Nutri-Strips™ on shelves at CVS, Amazon.com and Target.com. Nutri-Strips are proprietary to Sera Labs and are the result of years of research.
We have recently enhanced the reach and visibility of our Brand Ambassador, actress Nicole Kidman, as part of the launch of our new transformational Seratopical Revolution and Nutri-Strips marketing campaigns and the unveiling of our revolutionary new delivery system for our plant-based skincare line. Nicole Kidman and our CEO will have more prominence in these multi-faceted marketing programs including recent articles like the ones in Forbes and Impact Wealth. To view the articles, click on the following links:
Forbes Oct 31, 2022 - Nicole Kidman Talks Skincare-And The Beauty Essentials She Always Has In Her Bag
Impact Wealth Oct 31, 2022 - The Powerful Impact of Beauty Market Revealed by CEO Nancy Duitch
Board of Directors and Governance Update
On August 2, 2022, CURE announced the appointment of Gerald Bagg to its Board of Directors. This strategic addition adds depth to CPG and advertising. A 45+ year veteran of the advertising industry, Gerald is best known for pioneering the BRAND RESPONSE advertising approach to campaigns. He is the Chairman and a co-founder of Quigley-Simpson Inc., a more than twenty-year-old full-service advertising agency specializing in strategic planning, marketing, media planning and buying, brand building, creative development, and production. Quigley-Simpson clients include some of the largest consumer goods companies with some of the most well-known brands in the world including over 60 brands from Proctor & Gamble.
On August 16, 2022, the Company announced the appointment of former CURE CEO Rob Davidson as Chairman of its Board of Directors. In addition, the Company announced the appointment of Robert J. Costantino to its Board of Directors and he has also been appointed as Chairman of CURE's Audit Committee. Rob Davidson brings a deep understanding of the CURE pipeline and provides expertise in continued new product development, patent creation, and continuity in non-dilutive ongoing deal transactions as well as years of public company experience. Rob Costantino brings a unique combination of decades of financial expertise, investing experience and shareholder advocacy, operational experience, and many years of negotiating success in closing multi-billion-dollar total company and asset sales to S&P 500 companies.
Shareholder Value and Communication and Investor Events
With increasing shareholder value being a primary focus, the Company is continuing to work on additional initiatives to enhance shareholder value and is committed to increasing visibility and communications with shareholders. During the third quarter, the Company participated in three investor conferences in New York, Florida and California making presentations to investors, meeting with potential business development partners and conducting one-on-one meetings with investors. To view a replay of our CEO's October 25th presentation and Q&A click on the following link:
Link to Oct 25 2022 CEO presentation at LD Micro Main Event Investor Conference
Our CEO also recently presented and held one-on-one meetings with investors at the following investor conference with others to follow:
November 14th - Q4 Investor Summit in New York City
In summary, the recent $20 million asset sale has helped us increase our cash position and strengthen our balance sheet. Since the announcement of that non-dilutive deal and positive management and Board of Director additions, our team has been working diligently on several initiatives aligned with our guiding vision of enhancing shareholder value by utilizing our proprietary technology to differentiate ourselves from our competition and producing quality high-margin products with improved safety, efficacy, and consumer experience. Our new marketing programs are showing early encouraging results, as we continue to focus heavily on accelerating our high margin sales in the U.S. as well increasing our international presence and sales in the coming year, which is supported by our continuing work on new products and patents. We have strengthened our Board of Directors and Corporate Governance with recent Board and finance team additions including a strong Controller who joined us in November following the addition of a strong public company experienced Chief Financial Officer earlier this year. We have bolstered shareholder outreach through investor conferences across the country in the past two months and through other discussions to ensure that our turnaround strategy is universally understood and that we understand shareholders' key concerns. Our strategy is aligned with the interests of our investors and consistent with our overall guiding principle of driving long term shareholder value.
For further details, please visit our website to review our most recent Form 10-Q filed on November 21, 2022 at: http://www.curepharmaceutical.com/investors/sec-filings/
CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical is a broad platform technology company that develops proprietary nutraceutical and topical delivery systems and currently holds fifteen patents. The technology offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new innovative technology that is part of its incubator strategy.
About The Sera Labs, Inc.
The Sera Labs, Inc. ("Sera Labs"), a wholly-owned subsidiary of CURE, is a trusted leader in the wellness and beauty sectors utilizing cutting edge technology and high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale and is strategically positioned to grow its beauty and wellness products into household brands. Sera Labs products are sold Direct to Consumer with a subscribe and save option, as well as in major national drug, grocery and mass retailers. For more information visit: http://Seratopicalrevolution.com, http://Seratopical.com, http://Seralabshealth.com and follow Sera Labs on Instagram at @seratopical, as well as on Twitter and Facebook.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
Contacts:
Investor Relations
Hanover International Inc.
(760) 564-7400
investor@curepharma.com
SOURCE: CURE Pharmaceutical Holding Corp.
View source version on accesswire.com:
https://www.accesswire.com/727677/CURE-Pharmaceutical-Reports-Third-Quarter-2022-Results-With-Strong-Sequential-and-Year-Over-Year-Revenue-Increases-and-Continued-High-Margins
$AGYP signs MOU with Enerhash USA; here's the DD about the two companies! >>
https://drive.google.com/file/d/15VSrz2N-O0t5iq03zEO1JQgtSVUD-8YP/view
$PVSP Pervasip will provide a group of BCCTG owners, investors and employees 10.2% of Pervasip’s fully diluted equity in the form of restricted preferred stock.
“As outlined in our 24-months roadmap, which we published on September 6, 2022, this acquisition checks 2 of our boxes on the list of strategic objectives to be accomplished by year’s end 2022,” said German Burtscher, Pervasip’s CEO. “Not only will it immediately add revenue upon final closing of the deal, but it will also add infrastructure, expertise and a handful of well-regarded brands to our brand lineup. Brian Martin and his team at Emerald City Cultivation and Dabco have done incredible work and built a strong and highly respected company. We are excited to add the BCCTG team to our Washington operation and fill critical open positions with market leading expertise. Final terms will be released upon closing, projected for the end of November 2022.”
Emerald City Cultivation and Dabco are brands known for high quality concentrates product (dab and vape) and with over 40,000 followers have established a well-deserved fanbase.
“Combining forces with Artizen and offering a complete and potent product lineup to Washington retailers has been a vision of mine for some time now,” said Brian Martin, Founder and President of BCCTG and Emerald City Cultivation. “Being able to do this, take care of our investors who have been with us from the beginning of this venture, and join the Artizen team is a wonderful opportunity. Artizen is one of the original Washington State cannabis brands and our combined lineup will allow retailers to offer a variety of products across multiple price points, all from a single trusted partner. Combining our assets and experience will also allow us to enter markets outside of Washington and take our vision and duplicate it in other markets. Look out for more announcements regarding new products over the next few weeks and months.”
$PVSP Pervasip Corp. (OTC: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, together with Zen Asset Management LLC (“ZAM”) today announced the execution of a letter of intent (“LOI”) to acquire substantially all of the assets of BCCTG LLC (“BCCTG”).
BCCTG, owner of various brands, including Emerald City Cultivation, Emerald City Cured, Dabco, Dabs4Less and Vapes4less has agreed to terms to be acquired by ZAM, combining its brands and concentrate offerings with ZAM’s Artizen brands to form a powerful portfolio of brands, covering flower, pre-roll, dabbable concentrates and vape products.
BCCTG’s brands, which generate $4 million in annualized revenues, manufactured in a state-of-the-art laboratory. The terms include acquisition of all BCCTG assets, including its brands, access to a Tier 2 producer/processor license and a turnkey laboratory which will be used to also manufacture new products under the Artizen brand.
According to the terms of the LOI, Zen will acquire the assets of BCCTG for cash, paid from contributed revenues with a monthly upper limit and cash neutral on current pre-transaction financials. In addition, Pervasip will provide a group of BCCTG owners, investors and employees 10.2% of Pervasip’s fully diluted equity in the form of restricted preferred stock.
“As outlined in our 24-months roadmap, which we published on September 6, 2022, this acquisition checks 2 of our boxes on the list of strategic objectives to be accomplished by year’s end 2022,” said German Burtscher, Pervasip’s CEO. “Not only will it immediately add revenue upon final closing of the deal, but it will also add infrastructure, expertise and a handful of well-regarded brands to our brand lineup. Brian Martin and his team at Emerald City Cultivation and Dabco have done incredible work and built a strong and highly respected company. We are excited to add the BCCTG team to our Washington operation and fill critical open positions with market leading expertise. Final terms will be released upon closing, projected for the end of November 2022.”
Emerald City Cultivation and Dabco are brands known for high quality concentrates product (dab and vape) and with over 40,000 followers have established a well-deserved fanbase.
“Combining forces with Artizen and offering a complete and potent product lineup to Washington retailers has been a vision of mine for some time now,” said Brian Martin, Founder and President of BCCTG and Emerald City Cultivation. “Being able to do this, take care of our investors who have been with us from the beginning of this venture, and join the Artizen team is a wonderful opportunity. Artizen is one of the original Washington State cannabis brands and our combined lineup will allow retailers to offer a variety of products across multiple price points, all from a single trusted partner. Combining our assets and experience will also allow us to enter markets outside of Washington and take our vision and duplicate it in other markets. Look out for more announcements regarding new products over the next few weeks and months.”
$PVSP (GLOBE NEWSWIRE) -- Pervasip Corp. (OTC: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, together with Zen Asset Management LLC (“ZAM”) today announced the execution of a letter of intent (“LOI”) to acquire substantially all of the assets of BCCTG LLC (“BCCTG”).
BCCTG, owner of various brands, including Emerald City Cultivation, Emerald City Cured, Dabco, Dabs4Less and Vapes4less has agreed to terms to be acquired by ZAM, combining its brands and concentrate offerings with ZAM’s Artizen brands to form a powerful portfolio of brands, covering flower, pre-roll, dabbable concentrates and vape products.
BCCTG’s brands, which generate $4 million in annualized revenues, manufactured in a state-of-the-art laboratory. The terms include acquisition of all BCCTG assets, including its brands, access to a Tier 2 producer/processor license and a turnkey laboratory which will be used to also manufacture new products under the Artizen brand.
According to the terms of the LOI, Zen will acquire the assets of BCCTG for cash, paid from contributed revenues with a monthly upper limit and cash neutral on current pre-transaction financials. In addition, Pervasip will provide a group of BCCTG owners, investors and employees 10.2% of Pervasip’s fully diluted equity in the form of restricted preferred stock.
“As outlined in our 24-months roadmap, which we published on September 6, 2022, this acquisition checks 2 of our boxes on the list of strategic objectives to be accomplished by year’s end 2022,” said German Burtscher, Pervasip’s CEO. “Not only will it immediately add revenue upon final closing of the deal, but it will also add infrastructure, expertise and a handful of well-regarded brands to our brand lineup. Brian Martin and his team at Emerald City Cultivation and Dabco have done incredible work and built a strong and highly respected company. We are excited to add the BCCTG team to our Washington operation and fill critical open positions with market leading expertise. Final terms will be released upon closing, projected for the end of November 2022.”
Emerald City Cultivation and Dabco are brands known for high quality concentrates product (dab and vape) and with over 40,000 followers have established a well-deserved fanbase.
“Combining forces with Artizen and offering a complete and potent product lineup to Washington retailers has been a vision of mine for some time now,” said Brian Martin, Founder and President of BCCTG and Emerald City Cultivation. “Being able to do this, take care of our investors who have been with us from the beginning of this venture, and join the Artizen team is a wonderful opportunity. Artizen is one of the original Washington State cannabis brands and our combined lineup will allow retailers to offer a variety of products across multiple price points, all from a single trusted partner. Combining our assets and experience will also allow us to enter markets outside of Washington and take our vision and duplicate it in other markets. Look out for more announcements regarding new products over the next few weeks and months.”
$SNPW Nov. 15, 2022 (GLOBE NEWSWIRE) -- Sun Pacific Holding Corp. (Other OTC: SNPW) announces that its wholly owned subsidiary, Sun Pacific Power (“SPP”) is pleased to report on important progress on the company’s previously announced contract with Invictus to provide an insurance wrap for a $50 million-dollar funding of our planned US based solar manufacturing plant through Lloyds of London. After a process of detailed due diligence on the project, Invictus has identified and secured the non-binding support of one of the leading insurance practitioners on its preferred panel of "A" Investment Grade Credit Rated underwriters.
Operating within the Lloyd's of London insurance market, the contract certainty, experience, knowledge, and market reputation of this underwriter are beyond reproach. Through a process of coinsurance, the lead underwriter will issue the proposed suite of insurance policies and be the single point of contact for all correspondence and documentation to manage all claims, endorsements, and renewals. Invictus confirms that the preferred funding partner(s) will be formally endorsed to the complete suite of policies so that in the event of a successful claim the underwriters will be legally obligated to settle the monies directly to that funder.
Nicholas Campanella, CEO of Sun Pacific Holding Corp, stated, “It is extremely gratifying to see the swift action by Invictus to secure the high level “A” Investment Grade underwriter support which will now help move the financing for our planned solar power project forward to its next stage. We have already located a well suited 200k sq ft property in Alabama that will meet all of our facility requirements and be able to produce over 1GW of solar panels per year for our customers. This project should become a cornerstone of the SNPW renewable energy business plan in the near future.”
$SMME The SmartMetric biometric credit card has been designed and developed by SmartMetric engineers and product development designers https://www.smartmetric.com/
$XALL Xalles Holdings Inc. is a holding company that focuses on direct investments in disruptive fintech companies. The company actively seeks acquisition targets in which it can invest and accelerate growth, targeting companies with solid management teams and business models, large total attainable markets (TAM), and lucrative exit opportunities. The company places emphasis on leveraging blockchain technologies to provide industry-leading financial reconciliation and auditing solutions, which, over time, will allow for the capture of recurring revenue streams. For more information visit: Xalles.com
$JUPWJupiter Wellness Appoints Ardis Enterprises as the Exclusive Florida Market Distributor for its NoStingz and CaniSun Lines of Sunscreen https://finance.yahoo.com/news/jupiter-wellness-appoints-ardis-enterprises-133000478.html
$MASN big increase in revenues for the company: Maison Luxe ($MASN) revenues grew 35% compared to the quarter ended September 30, 2021 $AVXL $COSM $MASN https://www.benzinga.com/pressreleases/22/12/ab29954104/maison-luxe-masn-revenues-grew-35-compared-to-the-quarter-ended-september-30-2021 via @Benzinga
$AMFL The Street Reports Podcast Features American Film Inc’s (OTCQB: AMFL) Founder Tom Murphy Listen
https://thestreetreports.com/the-street-reports-podcast-features-american-film-incs-otcqb-amfl-founder-tom-murphy-listen-now/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |